Accessibility Menu
CureVac logo

CureVac

(NASDAQ) CVAC

This security has been delisted. This page is retained for historical reference.

CureVac last closing stock price
MetricPriceDate
Last closeUSD 4.662026-01-05
CureVac stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+7.87%USD 4.322025-12-29
1 month-8.98%USD 5.122025-12-05
3 month-14.18%USD 5.432025-10-07
Year to date+3.1%USD 4.522025-12-31
1 year+28.73%USD 3.622025-01-03
3 year-43.58%USD 8.262023-01-06
5 year-94.63%USD 86.852021-01-06
Since inception-91.66%USD 55.902020-08-14

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

CVAC Financials

Key Financial Metrics (TTM)

Gross Margin

93.85%

Operating Margin

344.28%

Net Income Margin

287.15%

Return on Equity

23.04%

Return on Capital

24.16%

Return on Assets

14.19%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

N/A

Volume

N/A

Avg. Volume

N/A

Financials (TTM)

Gross Profit

€65.79M

Operating Income

€149.98M

EBITDA

€181.23M

Operating Cash Flow

-€120.14M

Capital Expenditure

-€4.96M

Free Cash Flow

-€125.10M

Cash & ST Invst.

€419.21M

Total Debt

€35.07M

CureVac Performance Analysis

CureVac annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20212021-12-31EUR 121,732,215N/A
20222022-12-31EUR 70,856,688-41.8%
20232023-12-31EUR 58,118,613-18.0%
20242024-12-31EUR 578,899,259896.1%
CureVac sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-12-31-97.1%
Q12025-03-31-93.8%
Q22025-06-3039.4%
Q32025-09-304248.1%
CureVac annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20212021-12-31EUR -2.62N/A
20222022-12-31EUR -1.38-47.1%
20232023-12-31EUR -1.27-8.0%
20242024-12-31EUR 0.78N/A
CureVac sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-12-31-109.9%
Q12025-03-31-53.3%
Q22025-06-30-13.0%
Q32025-09-30565.4%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q3 2025YOY CHG

Revenue

€54.13M

-89.0%

Gross Profit

€53.76M

-88.6%

Gross Margin

99.31%

N/A

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

N/A

N/A

Employees

825

N/A

Net Income

€273.23M

-19.2%

EBITDA

€317.86M

-15.3%

Quarterly Fundamentals

Name
Q3 2025YOY CHG

Total Cash

€419.21M

-24.5%

Total Debt

€35.07M

-12.6%

Accounts Receivable

€27.36M

+31.5%

Inventory

€541.00K

+15.1%

Long Term Debt

€30.30M

-13.2%

Short Term Debt

€4.77M

-8.9%

Return on Assets

14.19%

N/A

Return on Invested Capital

21.47%

N/A

Free Cash Flow

€29.54M

-91.6%

Operating Cash Flow

€29.86M

-91.6%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
NVAXNovavax, Inc.
$8.21-0.36%
NKTRNektar Therapeutics
$68.26+1.80%
SNDXSyndax Pharmaceuticals, Inc.
$22.80+0.40%
INBXInhibrx Biosciences Inc.
$87.39-1.89%

Trending Stocks

Symbol / CompanyPricePrice Chg
ONDSOndas
$6.53-0.02%
AALAmerican Airlines Group
$14.98-0.04%
NOKNokia
$10.12-0.03%
PATHUiPath
$12.15+0.01%

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.